Cellectar Biosciences Inc.
| NASDAQ: CLRB | Healthcare / Biotechnology / USA |
| 2.47 | +0.2300 | +10.27% | Vol 344.93K | 1Y Perf 19.15% |
| Nov 30th, 2023 16:00 DELAYED |
| BID | 2.36 | ASK | 2.51 | ||
| Open | 2.21 | Previous Close | 2.24 | ||
| Pre-Market | - | After-Market | 2.48 | ||
| - - | 0.01 0.40% |
| Target Price | 12.60 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 410.12 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/100 | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/-/100 | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/100 | Income Ranking | — - | |
| Price Range Ratio 52W % | 64.21 | Earnings Rating | Strong Sell | |
| Market Cap | 30.35M | Earnings Date | 2nd Nov 2023 | |
| Alpha | -0.03 | Standard Deviation | 0.20 | |
| Beta | 1.12 |
Today's Price Range 2.212.54 | 52W Range 1.253.15 | 5 Year PE Ratio Range -3.10-0.7000 |
Summary:
Buy
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | 17.62% | ||
| 1 Month | 3.78% | ||
| 3 Months | 35.71% | ||
| 6 Months | 51.53% | ||
| 1 Year | 19.15% | ||
| 3 Years | 63.04% | ||
| 5 Years | 10.76% | ||
| 10 Years | -99.68% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -62.47 | |||
ROE last 12 Months | -127.34 | |||
ROA (5Y Avg) | -24.49 | |||
ROA last 12 Months | -99.54 | |||
ROC (5Y Avg) | -103.61 | |||
ROC last 12 Months | -111.22 | |||
Return on invested Capital Q | -51.05 | |||
Return on invested Capital Y | -17.03 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | - |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -0.40 | ||||
| 1.53 | ||||
| - | ||||
| - | ||||
| -1.00 | ||||
| -3.65 | ||||
| 1.53 | ||||
| 1.21 | ||||
| 1.16M | ||||
| Forward PE | -0.91 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 2.70 | ||||
| 2.90 | ||||
| 0.00 | ||||
| 0.02 | ||||
| - | ||||
| Leverage Ratio | 1.40 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2023 | -0.69 | -0.73 | -5.80 |
| Q01 2023 | -0.75 | -0.76 | -1.33 |
| Q04 2022 | -0.83 | -0.55 | 33.73 |
| Q03 2022 | -1.21 | -1.28 | -5.79 |
| Q02 2022 | -1.08 | -1.22 | -12.96 |
| Q01 2022 | -1.10 | -1.00 | 9.09 |
| Q04 2021 | -1.00 | -1.00 | 0.00 |
| Q03 2021 | -1.10 | -1.00 | 9.09 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 12/2023 QR | -0.61 | -10.91 | Negative |
| 12/2023 FY | -2.85 | -24.45 | Negative |
| 3/2024 QR | -0.56 | 75.86 | Positive |
| 12/2024 FY | -2.30 | - | - |
| Next Report Date | - |
| Estimated EPS Next Report | -0.44 |
| Estimates Count | 2 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 344.93K |
| Shares Outstanding | 12.29K |
| Shares Float | 10.08M |
| Trades Count | 1.61K |
| Dollar Volume | 826.58K |
| Avg. Volume | 347.16K |
| Avg. Weekly Volume | 137.63K |
| Avg. Monthly Volume | 174.16K |
| Avg. Quarterly Volume | 729.69K |
Cellectar Biosciences Inc. (NASDAQ: CLRB) stock closed at 2.47 per share at the end of the most recent trading day (a 10.27% change compared to the prior day closing price) with a volume of 344.93K shares and market capitalization of 30.35M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 8 people. Cellectar Biosciences Inc. CEO is James V. Caruso.
The one-year performance of Cellectar Biosciences Inc. stock is 19.15%, while year-to-date (YTD) performance is 44.44%. CLRB stock has a five-year performance of 10.76%. Its 52-week range is between 1.25 and 3.15, which gives CLRB stock a 52-week price range ratio of 64.21%
Cellectar Biosciences Inc. currently has a PE ratio of -0.40, a price-to-book (PB) ratio of 1.53, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -99.54%, a ROC of -111.22% and a ROE of -127.34%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Cellectar Biosciences Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.44 for the next earnings report. Cellectar Biosciences Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Cellectar Biosciences Inc. is Strong Buy (1), with a target price of $12.6, which is +410.12% compared to the current price. The earnings rating for Cellectar Biosciences Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Cellectar Biosciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Cellectar Biosciences Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 13.31, ATR14 : 0.18, CCI20 : 86.84, Chaikin Money Flow : -0.07, MACD : -0.04, Money Flow Index : 63.98, ROC : 27.32, RSI : 58.98, STOCH (14,3) : 89.55, STOCH RSI : 1.00, UO : 55.79, Williams %R : -10.45), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Cellectar Biosciences Inc. in the last 12-months were:
Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical stage biopharmaceutical company. It focusses on development of targeted phospholipid drug conjugates for the treatment and imaging of cancer. The company's pipeline consists of pre-clinical and clinical product candidates including radiotherapeutic and chemotherapeutic phospholipid drug conjugates. Its portfolio of products in development includes CLR 131, CTX Product Portfolio consisting of CTX CLR 1800-P, CTX CLR 1602-PTX and CTX CLR 1700, CLR 125, CLR 124, and CLR 1502.
CEO: James V. Caruso
Telephone: +1 608 441-8120
Address: 100 Campus Drive, Florham Park 07932, NJ, US
Number of employees: 8
